Pharmaceutical R&D and Manufacturing
Pharmaceutical Scale-Up Research & Development: From Lab to Commercial Production
A practical, science-led guide to translating a promising laboratory process into a reproducible manufacturing process—through process understanding, pilot studies, risk-based decisions and structured technology transfer.
Pharmaceutical scale-up is the planned transfer of product and process knowledge from laboratory or development batches to pilot, engineering and commercial manufacturing. A sound scale-up program identifies critical material attributes and process parameters, predicts what may change with equipment and batch size, tests those predictions at appropriate scales, and uses the results to refine the control strategy and support process qualification.
A process that performs well in a beaker, bench-top granulator or small reactor may behave differently in larger equipment. Batch depth, mixing pattern, heat removal, air movement, shear, residence time and operator or control-system interactions can all change as scale increases. Pharmaceutical scale-up research and development is the disciplined work of understanding those changes, testing their impact and preparing a process that can repeatedly make product of the intended quality.
What is pharmaceutical scale-up?
Pharmaceutical scale-up is the development activity that moves a formulation and manufacturing process from a smaller research or development scale toward the equipment, batch size and operating environment intended for routine production. It may apply to drug substances, oral solids, liquids, creams, sterile products, biologics and other dosage forms. Each has different physical and quality risks, so the scale-up plan must be specific to the product and its process.
Scale-up is closely related to process development, pilot manufacturing and technology transfer, but the terms describe different parts of the work:
- Process development establishes how materials and unit operations can produce the desired product attributes.
- Scale-up evaluates how that process behaves at increasing scales and with different equipment.
- Technology transfer communicates and verifies the product and process knowledge needed at a receiving site or line.
- Process qualification and validation use the accumulated evidence to demonstrate that the commercial process can operate reproducibly under defined conditions.
These activities overlap over the product lifecycle. FDA describes process validation as a lifecycle approach and identifies process design as the stage in which the commercial process is defined using knowledge gained during development and scale-up. The principles are compatible with a risk-based cGMP system, although specific regulatory expectations depend on product type, market and application.
Why does scale-up need planned research?
Increasing batch size can change the conditions experienced by each particle, droplet, cell or fluid element. A larger vessel may have longer mixing times, different circulation zones and a different relationship between surface area and volume. A dryer may have nonuniform airflow across a deeper bed. A coating pan can expose tablets to a different spray and drying pattern. These changes may affect content uniformity, dissolution, particle size, moisture, potency, impurity profile or other quality attributes.
A deliberate scale-up program helps the development team:
- Identify process variables that influence product quality and determine which need tighter control.
- Distinguish true process effects from normal variation in raw materials, equipment and measurement.
- Select equipment and operating ranges that can be reproduced at the intended manufacturing site.
- Reduce failed engineering batches, avoidable deviations, waste and delays to supply.
- Produce a traceable rationale for technology transfer, control strategy and validation planning.
Core principle: Increasing a batch from 5 kg to 500 kg makes it 100 times larger by mass. It does not automatically make the impeller speed, drying time, granulation time, spray rate or compression force 100 times larger. Each parameter must be selected according to the process physics, equipment design, material behavior and quality evidence.
Scale-up stages from laboratory to commercial production
There is no single scale sequence that fits every product. A small-molecule tablet, a fermentation process and a sterile liquid may use different equipment and batch milestones. The stages below are a practical framework; the project team should define its own scale gates and acceptance criteria.
| Stage | Main purpose | Evidence to generate |
|---|---|---|
| Preformulation and process feasibility | Understand material behavior, product risks and plausible manufacturing routes. | Material characterization, compatibility, early process trials, analytical methods and preliminary risk assessment. |
| Laboratory development | Build formulation and unit-operation understanding at a manageable scale. | Screening studies, process ranges, initial CQA/CPP relationships, analytical results and documented learning. |
| Pilot scale | Test process concepts in equipment that represents important commercial features. | Scale-relevant mixing, heat and mass-transfer data, sampling plan, operating windows and transfer risks. |
| Engineering or demonstration batches | Test the intended site, line, utility, procedure and staffing arrangements before routine manufacture. | Equipment fit, batch-record usability, material flow, control-system performance, operator training and issue list. |
| Commercial process qualification | Evaluate the designed process at commercial scale under the applicable validation strategy. | Approved protocols, qualified equipment, trained personnel, defined sampling and objective process-performance evidence. |
| Continued process verification | Maintain confidence in routine process performance and detect drift. | Trend data, periodic review, deviations, yield and CQA/CMA/CPP signals, and improvement actions. |
The stage names and number of batches should not become a substitute for scientific reasoning. FDA has clarified that process validation is not reducible to a simplistic fixed formula such as completing three successful full-scale batches; the manufacturer must build and evaluate adequate process knowledge and reproducibility evidence for the specific process.
Start with the target product and quality attributes
Before changing scale, define what the process must deliver. A development team can use the Quality Target Product Profile (QTPP) to describe the intended product characteristics and identify the Critical Quality Attributes (CQAs) that matter for safety, efficacy, performance and manufacturability. The specific terminology and documentation depend on the development program, but the reasoning should be clear: which material and process conditions could affect each important product attribute?
Map three connected groups:
- Material attributes: particle size, polymorphic form, moisture, bulk density, viscosity, potency, bioburden or other properties relevant to the process.
- Process parameters: order of addition, mixing conditions, granulation endpoint, drying conditions, hold time, filtration rate, temperature, pressure or other controlled operating inputs.
- Product outcomes: assay, content uniformity, dissolution, particle-size distribution, residual moisture, sterility assurance, potency, impurity profile or other defined CQAs.
Not every measured variable is critical. Use risk assessment and experimental data to determine which variables could meaningfully affect a CQA and which can be monitored as supporting indicators. ICH Q8(R2) describes a science-based approach to pharmaceutical development and emphasizes justification when applying a design space or development knowledge from small or pilot scale to the proposed production scale. ICH Q9(R1) provides a current quality-risk-management framework for development and manufacturing decisions.
Choose a scale-up strategy that fits the process
Scale-up methods range from empirical transfer of a known process to mechanistic models and structured experiments. Most programs combine prior knowledge, equipment data, material characterization, risk analysis and experiments. The selected approach should address the dominant failure modes instead of pursuing a single elegant scale-up number.
| Approach | How it is used | Key caution |
|---|---|---|
| Empirical or experience-based | Use relevant prior products, equipment history and established operating knowledge to choose initial conditions. | Prior experience is useful only when material, equipment and process similarities are understood. |
| Geometric similarity | Preserve selected vessel, impeller, pan or equipment proportions across scales. | Commercial equipment may differ in geometry; matching dimensions does not guarantee matching flow or heat transfer. |
| Dimensional or engineering criteria | Compare parameters such as power per volume, tip speed, Froude number, Reynolds number, superficial gas velocity or heat-transfer area. | One criterion may improve one phenomenon while worsening another. Select based on the unit operation and product risk. |
| Design of experiments (DoE) | Vary factors systematically to estimate main effects, interactions and useful operating ranges. | Choose factors and responses with process knowledge; a statistical model cannot compensate for poor measurement or an unrepresentative scale. |
| Mechanistic or hybrid modeling | Use mass/energy balances, population balances, computational fluid dynamics or process models alongside experimental data. | Check model assumptions and verify predictions at a relevant scale before relying on them for control decisions. |
In practice, the team may preserve a selected engineering criterion as a starting point, then verify mixing, endpoint, product attributes and operating robustness with trials. More than one criterion can be relevant, and the best choice may change between development and the commercial process.
Batch-size scale-up calculation: a simple example
Formula quantities are often scaled by a batch-size ratio when the formulation composition remains the same. This arithmetic is useful for planning material quantities, but it does not set equipment parameters, compensate for potency, or predict the process yield.
Scaled theoretical ingredient quantity = Development quantity × Scale factor
Worked example
A development batch is 1.5 kg and the proposed batch is 150 kg:
- Scale factor = 150 kg ÷ 1.5 kg = 100.
- If the development formula uses 120 g of a particular excipient, the proportional theoretical quantity is 120 g × 100 = 12 kg.
This example assumes the formula is expressed on the same basis and composition. The approved master formula may also require correction for API potency, water content, salt/base equivalence, moisture basis, or other justified material attributes. Manufacturing overage, process loss, yield targets and sampling quantities must be handled under the approved formulation and batch-record rationale rather than added automatically to the scale factor.
Do not use this simple ratio to scale process settings. A mixing speed, spray rate, hold time, drying temperature or compression setting needs process-specific reasoning and confirmation. A batch can have the correct ingredient masses and still fail because the larger equipment creates a different process environment.
What changes in common pharmaceutical unit operations?
Consider the material pathway and the equipment together. The following examples show questions to answer during scale-up; they are not universal operating instructions or acceptance limits.
| Unit operation | Potential scale effect | Development data to consider |
|---|---|---|
| Blending | Fill level, vessel geometry, mixing time, segregation tendency and sampling location may change. | Blend endpoint, uniformity, tracer or assay results, blender loading, speed, time and discharge behavior. |
| Wet granulation | Liquid distribution, impeller/chopper flow, shear, torque response and endpoint may not match at larger scale. | Binder addition rate, liquid-to-solid ratio, impeller and chopper settings, torque/power trend, granule size and downstream performance. |
| Drying | Bed depth, airflow distribution, heat transfer and moisture gradients can affect drying time and endpoint. | Product temperature, inlet/outlet air conditions, airflow, loading, sampling location, moisture/LOD and uniformity of the dried bed. |
| Compression | Press speed, dwell time, feed-frame behavior, die fill and tooling differences may affect tablet weight and mechanical properties. | Force and dwell-time ranges, feeder settings, tablet weight, thickness, hardness/breaking force, friability and dissolution as relevant. |
| Coating | Pan load and geometry, spray pattern, atomization, drying capacity and tablet circulation affect coating uniformity. | Spray rate per product load, gun position, atomization, inlet/exhaust conditions, bed temperature, weight gain and appearance. |
| Liquid mixing | Vessel and impeller geometry may alter circulation, mixing time, shear, foaming and heat transfer. | Mixing time, addition sequence, viscosity, temperature profile, homogeneity, aeration and product-specific quality tests. |
| Filtration or sterile processing | Filter area, batch volume, flow/flux, hold time, pressure and aseptic transfers may change risk or process capability. | Filter sizing basis, compatibility, pressure/flow profile, integrity controls, bioburden strategy, hold times and applicable validation studies. |
| Bioprocess / fermentation | Oxygen transfer, carbon dioxide removal, heat removal, mixing and shear environment may change with vessel scale. | Product- and cell-specific parameters such as dissolved oxygen, gas transfer, mixing, temperature, pH, metabolic indicators and product quality. |
For blending and granulation, sampling design matters as much as the equipment recipe: a sampling plan must represent locations, discharge stages and the suspected sources of variability. For sterile or biological processes, use the relevant process-specific guidance and validated control strategy. Do not transplant a solid-dose scale-up rule into a bioreactor or sterile liquid process.
Design experiments that answer scale-up questions
Each study should have a decision it is meant to support. Before the run, document the question, the scale and equipment, the factors to vary, the responses to measure, sampling locations, analytical methods and the decision rule. This prevents “pilot batches” from becoming expensive production rehearsals that generate data without resolving uncertainty.
- Build the process map: list each unit operation, input material, equipment, intermediate and potential product-quality impact.
- Rank the risks: identify where scale changes could alter mixing, mass transfer, temperature, shear, residence time, transfer losses or operator intervention.
- Choose factors and responses: select measurable variables tied to the risk and to relevant CQAs. Define methods with suitable range and precision.
- Plan the scale comparison: use representative equipment or a justified scale-down model. Note differences in geometry, control system, utility supply and loading.
- Run, analyze and document: capture actual process profiles, not only set points; evaluate data against the predefined question and investigate unexpected results.
- Update the control strategy: revise process ranges, in-process tests, material controls, sampling or training based on the evidence.
DoE can efficiently assess multiple factors and interactions when the response surface is sufficiently understood and the experiment is designed appropriately. It is one useful tool, not a mandatory format for every scale-up. Prior knowledge, mechanistic understanding and focused confirmation studies can also provide strong evidence when justified.
Pilot and engineering batches: what should be learned?
Pilot equipment should represent the commercial process features that drive product quality or operational feasibility. A pilot vessel with a different impeller, dryer with a different airflow pattern, or coating pan with a different spray layout may still be valuable, but the team must explain what is and is not representative.
A pilot or engineering batch can help verify:
- Whether the proposed material addition and process sequence can be performed as written.
- How actual temperature, pressure, mixing, torque, flow or endpoint profiles compare with development data.
- Whether raw-material quantities, containers, transfer routes, cleaning and in-process sampling are practical at the site.
- Whether yields and intermediate properties are within justified expectations and whether process losses are understood.
- Whether operators, automation, utilities, alarms and batch documentation support repeatable execution.
Write a protocol before the run. It should define the objective, lot size, equipment, critical observations, sampling, tests, planned deviations, responsibilities and criteria for deciding whether the learning objective was met. Do not label a batch “commercially validated” merely because it was manufactured at a large scale or met selected final tests.
Analytical methods and sampling during scale-up
Analytical data connect process conditions to product quality. Methods used to compare scales should be suitable for their intended purpose, and sample collection should account for the process’s likely sources of variation. A single convenient sample may not represent a large blend, dryer load, reactor or filling run.
At development and pilot stages, the team may need enhanced sampling to learn the process. The commercial control strategy may use a different sampling frequency once the process is better understood. Document why the sample locations and time points are relevant, how samples are handled, and how data are evaluated. When results appear unexpected, preserve the original raw data and follow approved laboratory and deviation procedures.
Technology transfer and commercial readiness
Technology transfer should carry the reasoning behind the process, not only the latest batch formula. ICH Q10 describes technology transfer as a knowledge-transfer activity that supports manufacturing and quality control across the product lifecycle. A clear transfer package helps the receiving site understand which conditions are established, which remain uncertain and how to escalate an unexpected result.
A practical transfer package may include:
- Product and process overview, process flow diagram and current formulation or master formula.
- Material specifications, supplier or material-attribute risks, sampling and storage needs.
- Equipment descriptions, intended operating ranges, key geometry differences and required utilities.
- Evidence supporting process parameters, in-process tests, endpoints, hold times and sampling locations.
- Analytical methods, data interpretation rules, batch history, deviations and relevant development reports.
- Cleaning requirements, safety controls, training needs, automation recipes and change-control history.
- Open risks, scale differences, assumptions, mitigation actions and post-transfer monitoring plans.
Where new or changed equipment is used, define its intended function and qualification strategy before routine use. A lifecycle approach may include URS, DQ, IQ, OQ and PQ activities where appropriate. The extent should reflect risk, intended use and applicable requirements rather than a checklist alone.
Scale-up, process validation and continued verification
Scale-up builds the knowledge used to design the commercial process. Process qualification then evaluates whether the designed process, facility, equipment, utilities, controls and personnel can reproducibly perform at commercial scale. Continued process verification monitors routine manufacturing and trends process and product data to confirm that the process remains in a state of control.
FDA’s lifecycle approach describes three validation stages: process design, process qualification and continued process verification. It expects objective information and data from suitable laboratory, pilot and/or commercial-scale studies to support confidence in the process. The specific evidence and validation protocol must be appropriate to the product, process and current market requirements.
Keep scale changes under approved change control. Evaluate whether the change affects the registered process, control strategy, design space, equipment, batch size, site, analytical methods or validated state. Assess the regulatory pathway before implementation. Use a current process validation plan and connect unexpected outcomes to deviation investigation and, when needed, CAPA.
Common scale-up problems and how to prevent them
| Pitfall | Why it causes trouble | Preventive action |
|---|---|---|
| Multiplying all settings by the batch-size factor | Equipment behavior and physical transfer phenomena do not scale linearly with batch mass. | Separate formula arithmetic from process-parameter selection; justify parameters and confirm experimentally. |
| Choosing a convenient but nonrepresentative pilot unit | Different geometry or controls can hide commercial-scale risks. | Compare critical design features and state how each difference affects interpretation. |
| Using final testing as the only evidence | End-product tests may not reveal where or why the process changed, especially if sampling is limited. | Track process profiles, intermediates, endpoints and representative samples alongside release tests. |
| Transferring set points without a rationale | A number copied from small scale may not have the same process effect on a larger machine. | Transfer the basis for each parameter, acceptable range, alarm and adjustment rule. |
| Ignoring raw-material variability | Particle size, moisture, viscosity or potency differences can appear as a scale effect. | Characterize relevant attributes and use approved material controls and supplier information. |
| Unplanned changes during a pilot run | Ad hoc adjustments weaken interpretation and can obscure cause and effect. | Predefine adjustments, decision authority and deviation handling in the protocol. |
| Closing transfer with unresolved knowledge gaps | The receiving team may not know when process conditions are no longer acceptable. | List residual risks, define ownership and specify enhanced monitoring or follow-up studies. |
Pharmaceutical scale-up readiness checklist
- Is the target product profile clear, and are relevant CQAs defined?
- Are material attributes, process variables and their links to quality understood?
- Does each scale-up study have a documented question, protocol, sampling plan and decision rule?
- Are the selected pilot and commercial equipment similarities and differences recorded?
- Are scaled formula quantities distinguished from equipment settings, process losses and yield targets?
- Are analytical methods and sample collection suitable for the intended scale comparison?
- Are batch records, automation recipes, utilities, cleaning, safety and operator training ready?
- Have unresolved risks, deviations, assumptions and regulatory impact been assessed?
- Is the receiving site equipped to control the process and trend important data?
- Is the next lifecycle stage clearly defined, including qualification, validation and continued monitoring?
Frequently asked questions
What does scale-up mean in pharmaceutical R&D?
Scale-up means increasing the manufacturing scale while evaluating how changes in equipment, batch size and operating conditions affect process performance and product quality. It combines experimentation, engineering judgment and risk-based evidence.
Is scale-up just multiplying the formula?
No. Ingredient quantities may be scaled proportionally when formula composition and calculation basis remain the same. Process settings such as mixing speed, time, airflow, spray rate or compression conditions require process-specific justification and verification.
What is the difference between lab scale, pilot scale and commercial scale?
Lab scale is used for early formulation and process learning. Pilot scale tests selected process concepts in larger or more representative equipment. Commercial scale uses the intended manufacturing process and equipment for routine production. The exact batch sizes depend on the product and equipment.
How is a batch scale factor calculated?
Divide the target batch size by the development batch size. For example, increasing from 1.5 kg to 150 kg gives a factor of 100. This factor can scale theoretical formula quantities, but it does not determine equipment settings or automatically include yield losses, potency corrections or overage.
What should be kept constant during scale-up?
There is no single parameter that should always remain constant. Depending on the unit operation, the team may evaluate geometric similarity, power per volume, tip speed, heat-transfer conditions, airflow, residence time or another relevant variable. Select and verify criteria based on process risk and product quality.
Why do pilot batches matter?
Pilot batches can test whether process concepts and equipment assumptions remain valid at a more representative scale. They help identify mixing, heat-transfer, sampling, material-handling, control-system and documentation issues before commercial qualification.
Does every pharmaceutical process need a design of experiments?
No. DoE is a useful tool for evaluating multiple factors and interactions, but it is not the only way to build process knowledge. Prior data, focused experiments, mechanistic understanding and risk assessment may also be appropriate when their use is justified.
Are three successful commercial batches always enough to validate a process?
Do not treat a fixed batch count as a universal substitute for science-based process design and reproducibility evidence. The appropriate validation strategy depends on the process, product, risk, available knowledge and applicable regulatory expectations.
When does scale-up become process validation?
Scale-up generates knowledge used to define the commercial process. Process qualification evaluates whether that process, equipment, facility and control strategy can reproducibly perform at the intended scale. Continued process verification then monitors routine performance.
What documents should be included in a scale-up package?
A package commonly includes the process map, formulation, material controls, equipment comparison, operating parameter rationale, development reports, sampling plans, analytical methods, batch records, deviations, open risks, training needs and the technology-transfer and validation plans.
Conclusion
Successful pharmaceutical scale-up connects product goals to process behavior at every manufacturing scale. Define the quality attributes first, understand the material and equipment, design studies to resolve high-risk uncertainties, and document why proposed commercial settings are appropriate. Carry that knowledge into technology transfer, process qualification and ongoing monitoring so that commercial manufacturing is based on evidence rather than simple extrapolation.
Official references and further reading
- FDA, Process Validation: General Principles and Practices.
- FDA, Questions and Answers on Current Good Manufacturing Practice Regulations: Production and Process Controls.
- ICH Q8(R2), Pharmaceutical Development.
- ICH Q9(R1), Quality Risk Management.
- ICH Q10, Pharmaceutical Quality System.
- ICH Q8/Q9/Q10 Questions and Answers (R5), including points on design-space verification and scale-up.
This educational article presents general development principles. It does not replace current regulations, approved regulatory commitments, product-specific development data, site procedures or decisions made by the responsible Quality Unit and regulatory authorities.